NDA 204441/S-008

SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING REQUIREMENTS

Otsuka Pharmaceutical Company, Inc.
Attention: Aditi Shah, MSc.
Manager, Global Regulatory Affairs
508 Carnegie Center Drive
Princeton, NJ 08540

Dear Ms. Shah:

Please refer to your supplemental new drug application (sNDA) dated and received May 7, 2020, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Jynarque (tolvaptan) 15 mg, 30 mg, 45 mg, 60 mg, 90 mg Tablets.

This Prior Approval supplemental new drug application provides for the deletion of sections 7.2 and 7.3 of the Drug Interactions section, and the addition of a description of the results of drug-drug interaction studies performed to section 12.3. There were additional editorial changes made throughout the label. There were no changes to the Medication Guide.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

FULFILLMENT OF POSTMARKETING REQUIREMENT(S)/COMMITMENT(S)

We have received your submission dated May 7, 2020, containing the final reports for the following postmarketing requirements listed in the April 23, 2018 approval letter.

3384-2 Conduct a clinical drug interaction study to evaluate the potential interaction between tolvaptan and a relevant BCRP substrate.

Draft Protocol Submission: 01/2019
Final Protocol Submission: 03/2019
Trial Completion: 09/2019
Final Report Submission: 03/2020

3384-3 Conduct a clinical drug interaction study to evaluate the potential interaction between DM-4103 and a relevant OATP1B1/3 substrate.

Draft Protocol Submission: 03/2019
Final Protocol Submission: 06/2019
Trial Completion: 11/2020
Final Report Submission: 03/2021

3384-4 Conduct a clinical drug interaction study to evaluate the potential interaction between DM-4103 and a relevant OAT3 substrate.

Draft Protocol Submission: 03/2019
Final Protocol Submission: 06/2019

[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

Trial Completion: 11/2020
Final Report Submission: 03/2021

We have reviewed your submission and conclude that the above requirements were fulfilled.

We remind you that there is a postmarketing requirement listed in the April 23, 2018 approval letter that is still open.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Lori Anne Wachter, RN, BSN, RAC, Regulatory Project Manager for Safety, at 301 796-3975.

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, PharmD
Deputy Director for Safety
Division of Cardiology and Nephrology
Office of Cardiology, Hematology, Endocrinology and Nephrology
Center for Drug Evaluation and Research

ENCLOSURE(S):
- Content of Labeling
  - Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MARY R SOUTHWORTH
10/19/2020 03:37:28 PM